Abstract Genetic differences among individuals can explain some of the variability observed during drug treatment. Many studies have correlated the different pharmacological response to genetic variability, but most of them have been conducted on adult populations. Much less attention has been given to the pediatric population. Pediatric patients constitute a vulnerable group with regard to rational drug prescribing since they present differences arising from the various stages of development. However, only a few steps have been made in developmental pharmacogenomics. This review attempts to describe the current methods for pharmacogenetic and pharmacogenomic studies, providing some of the most studied examples in pediatric patients. It also gives an overview on the implication and importance of microRNA polymorphisms, transcriptomics, metabonomics, and proteomics in pharmacogenetics and pharmacogenomics studies.
Introduction
After more than 50 years of pharmacogenetics (PGt) and pharmacogenomics (PGx) research, we have learned that genetic differences among individuals can explain some of the variability observed in the pharmacokinetics, efficacy, and toxicity of some drugs. Indeed, the magnitude of variation in the pharmacokinetics of a drug caused by genetic variants often far exceeds the range considered as acceptable when comparing the bioavailability of two different drug formulations [1] . Furthermore, there is evidence that consideration of PGt when prescribing drugs could significantly improve the safety and efficacy of therapy [2, 3] .
The term pharmacogenomics refers to the investigation of variations in DNA and RNA characteristics as related to drug response, while pharmacogenetics is a subset of PGx and is defined as the influence of variations in DNA sequence on drug response [4] . An increasing number of examples describing differences in drug response as a result of genetic polymorphisms and gene expression have been published, but most of these reports include only adult individuals. Few studies deal with PGx of children and highlight the most important difference between children and adults. This review seeks to describe the main biological differences in drug metabolizing capabilities between children and adults, to give an overview of the rapidly evolving research fields of both PGt and PGx, and also to illustrate what impact these studies can have on the development of personalized medicine in pediatric patients.
Response to the drugs: what is the difference between children and adults?
Human development, from the prenatal period through to adolescence, is a dynamic process. Newborns and infants rapidly undergo simultaneous stages of organ growth and demonstrate large variability in drug response and metabolizing capabilities [5] . Drugs may have different actions on individuals, not only within the adult population but also in children, because of genetic polymorphisms. There are several demonstrations of adverse drug reactions, with even fatal effects, due to the presence of genetic variations in drug metabolism that alter the levels of active drugs and metabolites. One frequently cited example is the morphine poisoning in a breastfed neonate of a codeine-prescribed mother who was afterward classified as an ultra-rapid metabolizer for CYP2D6 polymorphism. Since the frequency of CYP2D6 ultra-rapid metabolizer genotypes ranges from 1% in Finland and Denmark to 10% in Greece and Portugal, and 29% in Ethiopia, this polymorphism is clinically relevant [6] . CYP2D6 polymorphisms are clinically significant also for atomoxetine treatment, which was approved in 2002 for the treatment of attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults, as well as methylphenidate (MPH), the most commonly prescribed psychostimulant in ADHD-affected children, as described later in this review. CYP2D6 genotyping may be beneficial in preventing overdosing and subsequent ADRs or early cessation. Moreover, recently it has been demonstrated that recognizing intermediate metabolizers is clinically important because these children receive tailored therapeutic advice based on their genotype [7] .
While the effect of genetic variations in drug metabolism is known, much less attention has been given to developmental pharmacogenomics. Some genes are expressed much more in early life than they are in adults. One of the best examples of gene switching is represented by CYP3 gene family: CYP3A7 expression level is detectable as early as 50 to 60 days into gestation in fetal liver, and its expression begins to decline after the first postnatal week, reaching nondetectable levels in most individuals by 1 year of age. Simultaneously, hepatic CYP3A4/3A5 expression begins to dramatically increase at about 1 week of age, reaching 30% of adult levels by 1 month. So, total CYP3A protein expression over the entire developmental period remains constant. However, because CYP3A7 and CYP3A4 exhibit differences in substrate specificity and catalytic efficacy, some differences in metabolic capacity during development are observed [8] . If it is true that many genes are expressed much more in early life than they are in adults, it is also true that many drug metabolizing enzymes (DME) are less developed in children than in adults. An example is the UDP glucuronosyltransferase (UGT), which is a liver enzyme essential for the body's elimination of xenobiotic substances as well as endogenous substances including endogenous toxins and bilirubin. Only 1% of the normal adult level of hepatic bilirubin-UGT activity is present at birth [9] . Post-natal maturation of bilirubin-UGT is birth related, and increases rapidly to adult levels by 14 weeks, regardless of the gestational age at birth [10] , maybe in relation to the methylation or acetylation status of this locus.
The application of pharmacogenetic and pharmacogenomic approaches to the treatment of pediatric diseases requires an appreciation of these dynamic changes in gene expression. It is assumed that drug effects differ in children, but in reality this perception often arises because the drugs have not been adequately studied in pediatric populations of different ages and with different diseases [11] . Moreover, part of the reason for the perception that pharmacodynamics is different in children is because the pharmacokinetics may be different at different ages. However, advances in this field have been hampered by several problems. Most reports on the developmental expression of DMEs have limited their studies to short time frames of development, and many have depended on a small number of tissue samples, mostly confined to the hepatic expression during fetal development. Furthermore, there is also a paucity of information regarding changes during early childhood or at puberty [8] . While pharmacogenetics, as the study or clinical testing of genetic variation that gives rise to differing responses to drugs, might be considered similar in adults and children, "pharmacogenomics," as the study of how interacting systems of genes determine drug response [12] , is particularly appealing in a pediatric and developmental context because this definition captures the essence of the developmental processes that characterize maturation from the time of birth through to adulthood [5] .
Methods for pharmacogenetics and pharmacogenomics studies
In this section, we consider recent genetic and genomic strategies for identifying genetic and genomics variations that influence the response to particular treatments or therapies. We describe common methodological approaches that can be applied to pharmacogenetics and pharmacogenomics studies for both children and adults.
Case-control association studies: from candidate genes to genome-wide screen One of the most common study designs used to assess pharmacogenetic effects is that of the case-control association study. In the context of pharmacogenetics, the usual approach is to examine the active treatment arm of a clinical trial and divide subjects in the treatment arm into those with a positive response to the drug and those with a negative or no response. These two groups then constitute cases and controls who are genotyped for a particular candidate gene thought to be related to the treatment phenotype.
The problem with such studies is that, though they are easy to perform, they are fraught with a host of potential biases or difficulties in interpretation. Four design issues must be considered in any genetic case-control association study.
1. The major problem in case control studies is ensuring a good match between the genetic background of cases and controls, so that any genetic difference between them is related to the disease under study and not to biased sampling. Clearly, cases and controls should be from similar ethnic groups. More subtle genetic differences can be guarded against by collecting controls from the same geographical area as cases, or by collecting information such as the birth place of grandparents to check a similar distribution between cases and controls. Matching of cases and controls for ethnicity and the use of multiple unlinked markers to assess the presence of this confounding variable are useful techniques to detect or eliminate the potential bias of population stratification [13] . 2. The key determinant of quality in an association study is sample size. With the remote chance of finding common genes with large effects, studies must be powered to detect variants that are common but have low relative risk, or that are rare but have a higher relative risk, which means sample sizes of thousands. Rare variants with low relative risks are largely beyond the reach of genetic epidemiology because of the massive sample size that would be needed [14] . 3. An additional criterion for evaluation of the quality of the case-control study is assessment of Hardy-Weinberg equilibrium in the markers studied within the control group. Hardy-Weinberg equilibrium implies that the genotype frequencies can be determined directly from the allele frequencies and provides a check to ensure that genotyping errors, mutation, or population stratification do not explain observed results. 4. The final key to these studies is replication, which can be performed with a second case-control association study or a family-based study. Replication performed with family-based designs can be used in conjunction with a case-control association study.
Careful attention to these four issues that we have highlighted would go a long way to improving the quality of existing studies and preventing false-positive associations. However, we would like also to note that other issues can be addressed in any case-control association study such as selection of candidate gene polymorphism (bioinformatic tools), observation bias (phenotyping and genotyping methods), linkage disequilibrium, allele or genotyped analysis, multivariate analysis, gene-gene and gene-environment interaction, and correction for multiple comparisons.
The availability of very high throughput DNA analysis technologies [such as single nucleotide polymorphism (SNP) array] and the development of databases (HapMap project) harboring information about the genomic positions of DNA sequence variations have provided geneticists with efficient and powerful tools for identifying inherited DNA sequence variations that contribute to phenotypic expression and variability. In fact, it is now possible to test literally hundreds of thousands, if not a million or so, polymorphic markers for association with a particular phenotype in a single study. This kind of study focus on as many variations as possible in the absence of a priori knowledge is called genome-wide association study (GWAS).
Each study can look at hundreds or thousands of SNPs at the same time. Researchers use data from this type of study to pinpoint genes that may contribute to a person's risk of developing a certain disease. Because GWASs examine SNPs across the genome, they represent a promising way to study complex, common diseases in which many genetic variations contribute to a person's risk. This approach has already identified SNPs related to several complex conditions including diabetes, heart abnormalities, Parkinson's disease, and Crohn's disease. A few GWASs have been performed to discover SNPs involved in drug therapy. Results of the 12 pharmacogenomics GWASs published so far are summarized in a recent review by Crowley et al. [15] , as well as in the NHGRI GWAS catalog [16] . Six GWASs evaluated the association of genetic variation with drug efficacy, five evaluated adverse effects, and one examined a dose-response relationship (warfarin) [17] .
GWASs have been recognized as an important approach for uncovering polymorphisms accounting for individual differences in drug efficacy and drug safety [18] . A vast reservoir of observational studies and randomized clinical trials (RCTs)-completed, ongoing, or planned-provides a largely untapped resource for pharmacogenomic studies of drug safety and efficacy. In particular, RCTs allow for precise measurement of drug exposure and consistent ascertainment of phenotype; randomization produces unbiased treatment assignments and helps balance unmeasured confounding factors [19] . Performing GWASs within clinical trials, in which more potentially interacting variables can be identified, measured, and controlled, improves efficiency. So far, only two GWASs have been conducted in drug clinical trials; each of these studies provides relevant insights for future research. Given their efficiency and potential for leading to useful clinical medicine and public health applications, it seems surprising that so few GWASs have been done in the field of pharmacogenomics, especially within clinical trials. The incentives for conducting such studies deserve closer evaluation, especially for the studies of childhood-disease treatment response.
Pharmacogenetics studies in childhood conditions
Genetic diversity is a consequence of differences in DNA sequences. There are multiple types of genetic variation including SNPs, copy-number variations (CNVs), variable number of tandem repeats (VNTR), microsatellite polymorphisms, and cytogenetic rearrangements. There is much scientific evidence that shows how genetic variation can determine impaired response to drugs (Table 1) . Here we present an overview of pharmacogenetic studies of the most common childhood conditions, such as attention-deficit/ hyperactivity disorder (ADHD), growth hormone deficiency (GHD), acute lymphoblastic leukemia (ALL), and asthma.
Attention-deficit/hyperactivity disorder Attention-deficit/hyperactivity disorder (ADHD) is a multifactorial disorder characterized by physical hyperactivity and behavioral disinhibition that typically emerges during childhood or adolescence and often persists into adulthood. There is an estimated approximately 70% response rate to methylphenidate (MPH), the most commonly prescribed psychostimulant, in ADHD-affected children [20, 21] . Pharmacogenetic studies suggest that interindividual differences in stimulant-response may be related to genetic influences [22] [23] [24] [25] [26] [27] [28] [29] . The search for candidate genes associated with ADHD has been largely driven by the understanding that medications for the disorder have drug targets in the catecholamine system. Genes associated with increased risk for ADHD are the dopamine transporter (DAT1) [25] , the dopamine receptors (DRD4 and DRD5) [30] , serotonin transporter (5-HTT), and synaptosomalassociated protein (SNAP-25) [31] [32] [33] . Other genes of potential interest in pharmacogenetic studies of ADHD include catehol-O-methyltransferase (COMT) [26] and the adrenergic α2-receptor (ADRA2A and ADRA1A) [27, 34, 35] (Table 1 ). However, some pharmacogenetic studies show conflicting results. For example, in some of them, individuals homozygous for the DAT1 10-repeat 480 bp-VNTR showed poorer outcome [23, 24] , whereas others report improved clinical outcome [28] or no effect [29] on MPH response.
Growth hormone deficiency GH replacement is standard therapy for children with short stature due to GH deficiency (GHD). The usual treatment is carried out with fixed doses of human recombinant GH (hGH) adjusted for body weight or surface [36] . Two of the most common isoforms of GHR in humans are generated by retention (full-length GHR, GHRfl) or exclusion of exon 3 (exon 3-deleted GHR, GHRd3) [37] . These isoforms present a widespread distribution in humans, with the frequency of each allele ranging from 68 to 75% for GHRfl and 25 to 32% for GHRd3 [37, 38] . In 2004, in a study conducted on two cohorts of 76 and 96 children of European descent with idiopathic short stature or who were born small for gestational age, it was demonstrated that patients with at least one GHRd3 allele presented 1.7 to 2 times more growth acceleration induced by hGH therapy than patients homozygous for the full-length isoform [38] . These observations have been confirmed in some but not all studies, so it remains unclear at this time as to whether the GHRd3 isoforms actually convey increased GH responsiveness. It will require a large-scale, prospective, wellcontrolled study with appropriate assessment of proteomic and genomic markers of GH action as well as auxological data to settle this issue. Nevertheless, this study served to open the door to the potential importance of genomic and proteomic biomarkers as indicators and predictors of GH responsiveness [39] . Another study, conducted by Jorge and colleagues, is a good example of a direct relation between genetic variability and adult height after long-term treatment with hGH, since there are only few data in the literature about long-term effects of drugs. The authors demonstrated that patients carrying at least one GHRd3 allele had a significantly better growth velocity in the first year of hGH replacement and achieved a taller adult height when compared with patients homozygous for GHRfl alleles [36] .
Acute lymphoblastic leukemia
The therapeutic class that could benefit more from PGt and PGx is cancer chemotherapy. Anticancer agents are often given at doses near those that produce toxicity, show wide interpatient variability in disposition and effects, and should be given at optimal doses for the best chance of cure. Cancer is the leading cause of death by disease in children between 1 and 15 years of age in the U.S.A., with leukemia continuing to cause the highest proportion (33%) of these deaths [40] . ALL accounts for about 25% of all cancers in children. Despite the significant progress in treatment of ALL, long-term event-free survival rates are currently almost 80%, with 20% of patients not responding to standard therapy [31] . Treatment response can be altered by polymorphisms in genes encoding enzymes that metabolize chemotherapeutic agents. The thiopurine methyltransferase (TPMT) genetic polymorphisms and mercaptopurine toxicity are one of the best-studied examples in pharmacogenetics. Although 23 [40] .
Other important genes involved in ALL therapy are those codifying for the enzymes of the glutathione-Stransferase (GST) family. The polymorphisms of these genes have been associated with increased cancer incidence, therapy-related cancers, and toxicity following chemotherapy [40, 44] . Polymorphisms of GSTM1, GSTP1, and GSTT1 exist in all populations. The GSTM1*0 (GSTM1 null) and GSTT1*0 (GSTT1 null) alleles represent deletions of GSTM1 and GSTT1 genes, respectively, and result in a loss of enzymatic activity [45] . The 1578 A>G transition in GSTP1 gives rise to the Ile105Val polymorphism, which confers reduced enzyme activity [46] ; it is associated with high etoposide clearance in African-Americans treated with steroids [47] . Methotrexate (MTX) is also an important chemotherapeutic drug in the treatment of ALL. Methylenetetrahydrofolate reductase (MTHFR) is an essential enzyme in the folate/ methotrexate metabolism pathway. About 10% of Caucasians show a genotypic variant of MTHFR (677C>T; Ala222Val), which encodes a protein with about 30% of the wild-type activity [48] . This SNP has been linked to hepatotoxicity following methotrexate treatment [49] . Another low-function variant of MTHFR results from the 1298 A>C (Glu429Ala) substitution; it has been reported to be protective for adult acute lymphocytic leukemia [50, 51] but not to alter effects of MTX in leukemia [52] (Table 1) .
Asthma
Asthma is the most common chronic disease among children. In 2002, >30 million U.S. individuals reported ADHD Attention-deficit/hyperactivity disorder, ALL acute lymphoblastic leukemia, GHD growth hormone deficiency, SNP single nucleotide polymorphism, DIP deletion/insertion polymorphism, VNTR variable number tandem repeat, MPH methylphenidate, MTX methotrexate, MTXPG methotrexate polyglutamate, HGVS Human Genetic Variation Society, PMID PubMed identifier having been diagnosed with asthma, including 122 per 1,000 children [53] . Agonists of β2 adrenergic receptor (ADRB2) are the most widely used drug in the treatment of asthma; it has been demonstrated that a common polymorphism in the coding region of ADRB2 gene influences the response to short-acting albuterol therapy in children with asthma (Table 1 ). Bleecker and colleagues have recently tested the drug response effect of ADRB2-coding polymorphism in two randomized studies, the first conducted on 2,250 asthmatics, the second on 405. The results of this important study showed no pharmacogenetics effect of this genetic variant on therapeutic response when the patients were treated with inhaled corticosteroids plus long-acting β2-agonists [54] . However this is one of the few examples of PGt application in clinical trials in childhood (the participants were aged 12 years or more) and mainly emphasizes the problem of small sample sizes in case control association studies that leads to false-positive or false-negative findings. The other two modalities of asthma treatment are corticosteroids and leukotriene modifiers, and polymorphisms of the genes (CRHR1, LTC4, ALOX5) involved in their modulation have been described (Table 1) . However, also in this field, contradictory results have been reported. For example, the LTC4S -444 A >C promoter polymorphism has been associated with a reduced risk of asthma exacerbations when compared with individuals homozygous for the reference allele [31, 55, 56] ; in other studies, this observation was not consistent [57, 58] (Table 1) .
The omics world: current state and future perspectives Implication and importance of miR-polymorphisms in pharmacogenomics MicroRNAs (miRNA) are small, single-stranded, 21-23 nucleotide-long, independent functional units of noncoding RNA [59] [60] [61] . Often referred to as the "micromanagers of gene expression," miRNAs are evolutionarily wellconserved and, by binding to the target transcript in the 3′-UTR, can inhibit the translation of proteins and destabilize their target mRNA [62, 63] .
Pharmacogenomics of miRNA is a novel and promising field of research that holds new possibilities for tailor-made medical therapy. MiRNA pharmacogenomics can be defined as the study of miRNAs and polymorphisms affecting miRNA function in order to predict drug behavior and to improve drug efficiency [64, 65] . MiRNA pharmacogenomics has strong clinical implications for several reasons: miRNAs are attractive drug targets, are differentially expressed in malignant versus normal cells and regulate expression of several important proteins in the cell [66] [67] [68] .
MiR polymorphisms can interfere with miRNA function resulting in loss of the miRNA-mediated regulation of a drug-target gene conferring drug resistance [62] . Therefore, these miR-polymorphisms have potential as predictors of drug response in the clinic and will result in development of more accurate methods of determining appropriate drug dosage based on a patient's genetic makeup, thus decreasing the likelihood of drug overdose [65] .
Transcriptomics, metabonomics, and proteomics: other research areas completing pharmacogenetics and pharmacogenomics
Transcriptomics [69] refers to the study of gene transcripts, generally analyzed by cDNA expression microarrays. Such cDNA expression studies have led to a number of exciting breakthroughs in basic science. For example, microarray analysis of certain tumors has been successful in correlating a particular microchip pattern with a patient's prognosis [70] . Recent works indicate that global gene-expression profiling using cDNA microarrays can identify genes with levels of expression that are related to drug response. An advantage of this strategy is that it includes all genes of potential importance and, therefore, might identify new therapeutic and diagnostic targets. Its disadvantage is that, as a nontargeted genome-wide approach, it is influenced by "noise" (that is, expression signals of irrelevant genes) and increases the number of false positives (that is, unimportant genes that are identified by chance). Identification of genes on the basis of mRNA expression relative to drug response is complementary to the identification of SNPs in genes that alter protein function and drug response. Moreover, this might lead to the identification of SNPs that are associated with altered mRNA expression of genes associated with drug response.
Acute lymphoblastic leukemia (ALL) is an ideal model system in which to assess global gene expression in cancer because it is a "liquid" tumor and therefore relatively homogeneous within a patient and because it is easy to isolate and characterize. Robust gene-expression profiling for diagnosis and classification of childhood ALL might ultimately represent a less labor-intensive and more automated alternative to the multiple methods that are currently used (for example, immunochemistry, cytogenetics, and molecular diagnostics) [71] [72] [73] [74] [75] . Studies of leukemia-cell gene-expression patterns might also reveal new prognostic features and therapeutic targets. For instance, gene profiles might ultimately be able to identify children for whom therapy is likely to fail (that is, those who will experience relapse) or those who are at high risk of therapy-induced second cancers [76] [77] [78] [79] .
The major limitation of microarray studies is the availability of the appropriate source of sampling blood or excreta (urine, saliva, sweat, breast milk, ejaculate, menses, feces) or tissue in which relevant cDNAs or proteins exist (dissected tumor, tissue biopsies, placenta, foreskin). It would be unethical and unreasonable to attempt to predict individual drug response outcomes from biopsies of liver, lung, kidney, or brain in healthy patients.
Metabonomics (also called "metabolomics") refers to the study of metabolite profiling [80, 81] . Although this field is similarly limited by the same sampling problems as transcriptomics, there is an important difference. The metabonome represents an integrated (systems biology) response, in real time, to all endogenous plus all exogenous stimuli (drugs, chemical exposures, occupation, lifestyle, nutrition, age, gender). Metabonomics thus might provide an exquisitely sensitive means to follow an individual patient's phenotype, as a function of age, nutrition, course of disease, or therapy. Accordingly, in principle, this technique offers great promise in personalized drug therapy and medicine but may also be subject to some of the pitfalls identified above for pharmacogenomics.
Metabonomics might therefore be considered analogous to a "liver profile" test in clinical pathology, except that metabonomics includes measurement of metabolites present at much lower concentrations and, accordingly, provides several orders of magnitude greater sensitivity (femtomolar to attomolar range). Even though metabolite profiling can be performed only on easily available samples-such as blood, urine or other excreta, dissected tumor, or biopsy tissues-this method still holds promise for clinical success, and might be regarded as an extension of the present practice of clinical pharmacology [82] . It seems practicable that, in the more distant future, metabonomics will help genomics to revolutionize and individualize drug therapy.
Proteomics, the study of all proteins encoded by the genome [83] , has also been successful in certain areas of basic research. Although a recent study [84] estimated an average of 3.0 human proteins per gene, others have estimated that the true number of proteins per gene might be considerably higher. Proteomics-like transcriptomics and metabolomics-suffers from the types of source that must be sampled, e.g., blood, excreta, or biopsy or tumor tissue in which relevant proteins exist. It is conceivable however that in the future proteomics investigators might identify certain protein profiles, similar to the way in which metabonomics can identify certain metabolite profiles, that might be useful for predicting adverse drug reactions long before they become overt. During the next several years, we expect to see the use of both metabonomics and proteomics to successfully complement genetics and genomics, particularly when the population under study is composed of children, as their drug response capability may be different at different ages.
Conclusions
Pharmacogenetics and pharmacogenomics hold out the promise of helping to achieve the goal of individualized drug therapy. Their translation into the clinical practice has been relatively slow both for adulthood diseases and for childhood diseases. Often pharmacogenetics and pharmacogenomics studies show contradictory results that reflect inconsistent research methods, small sample sizes, no replication study, no standardized outcome measures, or little consideration for potential covariates such as co-morbidity. Before pharmacogenomic testing can be effectively utilized clinically, more data are necessary from randomized controlled clinical trials to determine the efficacy and clinical utility. Nevertheless, there is no estimate of what and how much genetic variation in gene products involved in drug disposition is relevant in clinical practice and there are only few data on long-term adverse effects of drugs. We expect that future approaches will also use large-scale public genetic databases, such as the HapMap project, to elucidate linkage of genetic markers and drug effects in different populations, with the goal of identifying new genes and elucidating polygenic determinants of drug responses.
We also would like to emphasize that children should not be considered as small adults when we approach pharmacogenetic or pharmacogenomic studies. Children present differences arising from the various stages of development. Many patterns of ontological development in the systems of the body illustrate how pediatric patients can differ from adults. Genotypes do not always correspond with expected phenotypes, making the job of deciding how to treat childhood disease and apply genomic research to pediatric medicine all the more complex. The scientific and lay communities should work diligently and creatively to design research appropriate for pediatric populations. For instance, during the coming years, we expect to see genetics and genomics complemented by both metabonomics and proteomics. The impacts of pharmacogenetic and pharmacogenomic research already stand to greatly enhance the safety of treating children diagnosed with ALL, as TPMT-deficient individuals can be easily identified. Pharmacogenetic and pharmacogenomic study should be continually applied to pediatric populations in an effort to provide children the equity and hope for progress in treatment, discovery, and understanding of disease already present in adult populations.
